Share

Related Links

Related Stories

  • The long term cost of inferior database quality
    This month’s editorial is written by Antony J. Williams and Sean Ekins. “If I have seen further than others, it is by standing upon the shoulders of giants.”Isaac Newton
  • Targeting Epigenetics – Not Just Drugs for Cancer
    Epigenetics is effectively the study of changes in gene function by covalent modifications. Such modifications result in a stably heritable phenotype that does not involve a change in DNA sequence. There are effectively 2 routes by which such covalent changes can be effected; first by methylation of C5 cytosine bases located 5’ to guanosines. This route is referred to as the cytosine methylation code. In addition, the histone component of chromosomes can be covalently modified at the N-terminus, the so-called histone code.
  • MorphoSys initiates program against drug-resistant MRSA infections
    MorphoSys AG has announced a new proprietary development program against novel infectious disease targets. As part of this initiative, MorphoSys has signed a license and collaboration agreement with UK-based Absynth Biologics.
  • Collaboration discovers selective inhibitors against PI3Ka
    Numerate and Intellikine have announced the successful conclusion of their research collaboration to discover novel small-molecule compounds targeting the PI3K/mTOR signaling pathway.
  • Gentronix develops new approach to reducing attrition rates
    Gentronix’s specialized GreenScreen HC test aims to enable pharmaceutical companies to accurately test compounds for genotoxicity without disrupting simultaneous drug discovery processes.

Top 5 Stories

News

New solution for compounds against human kinome

13 July 2010

Promega Corporation has partnered with SignalChem Pharmaceuticals to launch a complete kinase solution for the profiling of lead compounds against kinases representative of all major families of the kinome.

Using this single platform, scientists can profile lead compounds in their own laboratories without a loss in sensitivity. The solution is accomplished by combining an expanding series of Kinase Enzyme Systems with Promega ADP-Glo™ Kinase Assay.

The Kinase Enzyme Systems – used in concert with the ADP-Glo Kinase Assay – provide all of the necessary tools for drug screeners to profile inhibitors against the human kinome for off-target effects. Each Kinase System is composed of a unique protein kinase enzyme, cognate kinase substrate and enzyme buffer and has been optimized and quality controlled with the ADP-Glo Assay.

‘This partnering of SignalChem’s kinase reagents with the Promega ADP-Glo detection assay for kinases is an ideal fit,’ said Jasbinder Sanghera, Ph.D., President and CSO of SignalChem Pharmaceuticals. ‘Now researchers can obtain all the necessary components to test protein kinase inhibition from a single source while still obtaining the level of sensitivity obtained with traditional radiometric assays.’

Each Kinase Enzyme System will be available as a stand-alone enzyme system or will be sold together with ADP-Glo Assay.

 

This article is featured in:
Companies and People  •  Pharmacology/ Therapeutics

 

Comment on this article

You must be registered and logged in to leave a comment about this article.